VIVES is a multi-sector fund that invests in projects with a positive societal impact
To meet the growing demand for agricultural production, traditional production methods will have to be complemented by new technologies that not only improve crop yields, but also increase their...
e-Peas stands for Electronic Portable Energy Autonomous Systems.
The company was founded in 2014 on the conviction that the trillions of connected IoT nodes that will be deployed in the next few...
ViroVet is a pioneering company dedicated to the development of innovative and disruptive technologies for the control of viral diseases in livestock. It develops antiviral drugs for complex...
Pierre Blondeau, CEO Upstreem :
"We have been working since 2017 with VIVES II, which has joined us since the beginning of our adventure. VIVES II team has an in-depth understanding of all aspects of...
Pierre Delatte, CTO and co-founder of CISSOID :
"With the VIVES fund, we have found a partner who understands the challenge of bringing technology from a university laboratory to the...
David Frenay, CEO Emolytics :
"Emolytics is a spin-off of the UCLouvain, founded in 2014 and acquired by Profacts in 2018. Emolytics has been supported by VIVES II Fund since its inception, as VIVES...
Proceeds will advance clinical development of Nuclidium’s true theranostic pipeline and expand its global production and manufacturing network for copper-based radiopharmaceuticals
Participation is
NVD003 is a bone grafting material developed to surgically treat patients with Congenital Pseudarthrosis of the Tibia, a rare and difficult-to-treat pediatric disease
Four young patients were treated
VIVES Partners’ portfolio investment The Akkermansia Company (TAC) acquired by Danone
Acquisition of TAC’s gut microbiota product, with benefits for people at risk of cardiovascular disease